Q4 2025 · 13F-HR
Samsara BioCapital, LLCholdings as filed
Filed 2026-02-17 · accession 0001744967-26-000002
$969.3M
Reported value
21
Positions
2025-12-31
Period end
The Brief · Samsara BioCapital, LLC · Q4 2025
AI · grounded in 13F
Samsara BioCapital, LLC established a new position in IVA valued at $24.16M. The fund also opened a new stake in RANI for $11.48M and increased its holding in JBIO by 82.39%. On the sell side, the fund closed its positions in LENZ and AVDL, reducing its exposure by $15.98M and $10.31M respectively.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 80706P103 | SRRK | SCHOLAR ROCK HLDG CORP | $303.8M | 31.3% | 6,897,652 | Common | SOLE |
| 603170101 | MLYS | MINERALYS THERAPEUTICS INC | $213.1M | 22.0% | 5,871,018 | Common | SOLE |
| 482929106 | KLRS | KALARIS THERAPEUTICS INC | $109.3M | 11.3% | 12,948,081 | Common | SOLE |
| 81734D104 | SEPN | SEPTERNA INC | $87.8M | 9.06% | 3,149,128 | Common | SOLE |
| 022307102 | ALMS | ALUMIS INC | $56.2M | 5.80% | 5,756,984 | Common | SOLE |
| 64135M105 | NGNE | NEUROGENE INC | $35.4M | 3.65% | 1,717,127 | Common | SOLE |
| 46124U107 | IVA | INVENTIVA SA | $24.2M | 2.49% | 5,194,805 | Common | SOLE |
| 38341P102 | GOSS | GOSSAMER BIO INC | $22.4M | 2.31% | 7,222,559 | Common | SOLE |
| 91678A107 | UPB | UPSTREAM BIO INC | $20.0M | 2.06% | 736,047 | Common | SOLE |
| 03843E104 | AQST | AQUESTIVE THERAPEUTICS INC | $16.1M | 1.67% | 2,500,000 | Common | SOLE |
| 008064206 | JBIO | JADE BIOSCIENCES INC | $14.9M | 1.54% | 968,798 | Common | SOLE |
| 918385204 | VTVT | VTV THERAPEUTICS INC | $11.9M | 1.23% | 298,496 | Common | SOLE |
| 753018100 | RANI | RANI THERAPEUTICS HLDGS INC | $11.5M | 1.18% | 8,500,000 | Common | SOLE |
| 697947109 | PVLA | PALVELLA THERAPEUTICS INC NE | $11.0M | 1.13% | 104,817 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $10.2M | 1.05% | 75,442 | Common | SOLE |
| 98420X202 | XFOR | X4 PHARMACEUTICALS INC | $7.8M | 0.81% | 1,960,000 | Common | SOLE |
| 65487U108 | NKTX | NKARTA INC | $6.5M | 0.67% | 3,507,666 | Common | SOLE |
| 03940C100 | ACLXGBX | ARCELLX INC | $4.0M | 0.41% | 60,873 | Common | SOLE |
| 869367201 | STRO | SUTRO BIOPHARMA INC | $2.4M | 0.24% | 204,503 | Common | SOLE |
| 21217B100 | CTNM | CONTINEUM THERAPEUTICS INC | $825,760 | 0.09% | 72,245 | Common | SOLE |
| 67080N119 | NUVB/WS | NUVATION BIO INC | $40,959 | 0.00% | 124,119 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.